AVS Bio Acquired Research Supplier Biorbyt
The move expands AVS Bio's portfolio by integrating a catalog of over 1 million research product SKUs.
Updated on Sept. 29, 2026 in Biotech
Live Poll
Do you believe consolidation of biotech firms generally helps accelerate innovation in life sciences?
AVS Bio has acquired the Cambridge-based research supplier Biorbyt, an entity founded in 2011. Biorbyt will continue to operate under its existing leadership team as part of the broader AVS Bio platform.
Why it matters
This consolidation integrates Biorbyt’s extensive ecommerce capabilities into AVS Bio’s existing infrastructure, aiming to accelerate the distribution of research materials across global markets.
The acquisition adds over 1 million SKUs to the AVS Bio platform, which currently manages operations across more than 20 facilities in North America and Europe.
The players
AVS Bio
A research supply provider with operations spanning North America and Europe, headquartered in Norwich, CT.
Biorbyt
A Cambridge, UK-based supplier of research products and reagents that maintains a catalog of over 1 million SKUs.
The details
AVS Bio intends to incorporate Biorbyt’s established ecommerce infrastructure to streamline its product distribution. Biorbyt, which specializes in research products, will maintain its current operational structure while contributing its catalog to AVS Bio's footprint across 20 global facilities.
Timeline
2011: Biorbyt was founded.
September 2026: AVS Bio acquired Biorbyt.
The Tech Race
This acquisition follows the industry pattern of consolidating specialized reagent catalogs to maximize global distribution efficiencies. AVS Bio’s expansion competes directly with broader life science supply platforms by absorbing niche, high-volume catalogs into a centralized infrastructure.
Research laboratories and institutional procurement teams should expect to see Biorbyt’s catalog integrated into the AVS Bio ordering workflow. The timeline for full platform migration remains unannounced, but customers can continue using existing Biorbyt channels for now.
The takeaway
The move signals a continued trend toward supply chain centralization in the research reagent sector. Interested parties should track AVS Bio’s official portal for updates on when the integrated product catalog will be available to all global customers.
Further reading
For more on the state of the research supply market, see Biotech.
Source note: This article includes information reported by Business Weekly.
Live Poll
Do you believe consolidation of biotech firms generally helps accelerate innovation in life sciences?
